Agios Pharm Asset Resilience Ratio
Agios Pharm asset resilience ratio. Agios Pharm (AGIO) has an Asset Resilience Ratio of 46.73% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Agios Pharm defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Agios Pharm (2011–2025)
Asset resilience ratio of Agios Pharm from 2011 to 2025. This chart shows how Agios Pharm's Asset Resilience Ratio has changed over time. Read Agios Pharm debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Agios Pharm's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Agios Pharm total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $517.93 Million | 46.73% |
| Total Liquid Assets | $517.93 Million | 46.73% |
Asset Resilience Insights
- Very High Liquidity: Agios Pharm maintains exceptional liquid asset reserves at 46.73% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Agios Pharm Industry Peers by Asset Resilience Ratio
Compare Agios Pharm's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Agios Pharm Asset Resilience Ratio by Year (2011–2025)
Agios Pharm asset resilience ratio by year from 2011 to 2025. The table below shows the annual Asset Resilience Ratio data for Agios Pharm.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 58.99% | $765.29 Million | $1.30 Billion | +9.84pp |
| 2024-12-31 | 49.15% | $817.46 Million | $1.66 Billion | -24.34pp |
| 2023-12-31 | 73.49% | $688.72 Million | $937.12 Million | +21.52pp |
| 2022-12-31 | 51.98% | $643.86 Million | $1.24 Billion | -4.84pp |
| 2021-12-31 | 56.82% | $816.89 Million | $1.44 Billion | +4.59pp |
| 2020-12-31 | 52.23% | $445.49 Million | $852.95 Million | -2.10pp |
| 2019-12-31 | 54.33% | $483.95 Million | $890.74 Million | -5.64pp |
| 2018-12-31 | 59.97% | $514.80 Million | $858.46 Million | +7.69pp |
| 2017-12-31 | 52.28% | $321.21 Million | $614.40 Million | -9.19pp |
| 2016-12-31 | 61.47% | $380.56 Million | $619.09 Million | +3.09pp |
| 2015-12-31 | 58.38% | $245.24 Million | $420.06 Million | -8.31pp |
| 2014-12-31 | 66.69% | $328.03 Million | $491.90 Million | +19.37pp |
| 2013-12-31 | 47.32% | $95.21 Million | $201.21 Million | +20.55pp |
| 2012-12-31 | 26.77% | $36.68 Million | $137.01 Million | -4.86pp |
| 2011-12-31 | 31.63% | $61.51 Million | $194.47 Million | -- |
About Agios Pharm
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment… Read more